Keppel Infrastructure has been awarded an engineering, procurement, and construction (EPC) contract to develop a 600MW state-of-the-art, advanced combined cycle gas turbine (CCGT) power plant.
A consortium comprising Mitsubishi Power Asia Pacific and Jurong Engineering awarded the EPC contract to Keppel.
The Keppel Sakra Cogen Plant, to be built in the Sakra sector of Jurong Island, will be the first hydrogen-ready power plant in Singapore.
In line with Keppel’s asset-light business model, the Keppel Sakra Cogen Plant will be owned by Keppel Sakra Cogen Pte. Ltd. (KSC), a wholly-owned indirect subsidiary of Keppel Infrastructure.
Keppel Asia Infrastructure Fund LP (KAIF) and Keppel Energy will hold 70 percent and 30 percent equity interests in KSC.
In addition, KSC and Keppel Energy will enter into a turnkey contract for developing the Keppel Sakra Cogen Plant.
The total investment for the Keppel Sakra Cogen Plant is expected to be around S$750 million.


Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
Drug pollution in water is making salmon take more risks – new research
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient
Ukraine minerals deal: the idea that natural resource extraction can build peace has been around for decades
How is Antarctica melting, exactly? Crucial details are beginning to come into focus
The UK is surprisingly short of water – but more reservoirs aren’t the answer
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 



